Top-line Phase IIb results for Pfizer's danuglipron in obesity disappoint

1 December 2023
pfizer_hq_entrance_large

US pharma giant Pfizer (NYSE: PFE) saw its shares price fall 6.9% to $28.29 after it revealed mixed, but ultimately disappointing, clinical results for its obesity candidate danuglipron.

Pfizer said that the Phase IIb clinical trial ( NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes, met its primary endpoint demonstrating statistically-significant change in body weight from baseline.

Maximum placebo-adjusted weight loss for danuglipron BID weight loss at 26 weeks was 9.5% versus Eli Lilly’s (NYSE: LLY) orforglipron (cross-trial) of 10.6% and at 32 weeks was 13% versus Lilly’s orforglipron (cross-trial) of 11%-12%. High rates of GI adverse events were observed at the top doses: up to 73% nausea, 47% vomiting, and 25% diarrhea.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical